

# Appendix 4E and Preliminary Final Report

Year Ended 30 June 2024

**Genetic Technologies Limited**

ABN 17 009 212 328

**ASX: GTG**

For personal use only

**Genetic Technologies Limited**

**Appendix 4E**

**Preliminary Final Report**

**Year Ended 30 June 2024**

<b>Name of entity:</b>	<b>Genetic Technologies Limited</b>
<b>ABN:</b>	<b>17 009 212 328</b>
<b>Year ended:</b>	<b>30 June 2024</b>
<b>Previous year:</b>	<b>30 June 2023</b>

**Results for announcement to the market**

				\$
Revenue for ordinary activities	Down	12%	to	7,664,784
Loss from ordinary activities after tax attributable to members	Up	2%	to	(12,017,219)
Net loss for the year attributable to members	Up	2%	to	(12,017,219)

**Distributions**

No dividends have been paid for declared by the group for the current financial year. No dividends were paid for the previous financial year.

**Explanations of results**

The group reported a loss for the year ended 30 June 2024 of \$12,017,219 (2023: \$11,750,923). The increased loss largely relates to research and development and employment expenditure to progress the group's trial and research activities.

At 30 June 2024 the group's net assets were \$1,830,414 (2023: \$11,162,576) with cash reserves of \$1,020,608 (2023: \$7,851,197).

The Appendix 4E financial report follows, with further details to be included in the audited financial statements to be released by 30 September 2024.

**Net tangible assets per security**

	<b>2024</b>	2023
	Cents	Cents
Net tangible asset backing (per security)	(0.24)	0.07

**Changes in controlled entities**

There have been no changes in controlled entities during the year ended 30 June 2024.

For personal use only

**Other information required by Listing Rule 4.3A**

- |  |     |
|--|-----|
| a. Details of individual and total dividends or distributions and dividend or distribution payments: | N/A |
| b. Details of any dividends or distribution reinvestment plans:                                      | N/A |
| c. Details of associates and joint venture entities:   | N/A |
| d. Other information   | N/A |

**Audit**

The financial statements are currently in the process of being audited. Audited financial statements along with the independent auditor report for the year end 30 June 2024 is expected to be released by the end of September 2024 with an unqualified opinion with a material uncertainty related to going concern.

# Genetic Technologies Limited

ABN 17 009 212 328

## *Preliminary Final Report – 30 June 2024*

### Financial statements

Consolidated statement of profit or loss and other comprehensive income	2-3
Consolidated statement of financial position	4-5
Consolidated statement of cash flows	6
Consolidated statement of changes in equity	7
Notes to the financial statements	8-26

These financial statements are consolidated financial statements for the group consisting of Genetic Technologies Limited and its subsidiaries. A list of subsidiaries is included in note 21.

The financial statements are presented in the Australian currency.

Genetic Technologies Limited is a company limited by shares, incorporated and domiciled in Australia.

Its registered office is:

60-66 Hanover Street  
Fitzroy VIC 3065

Consolidated statement of profit or loss and other comprehensive income  
For the year ended 30 June 2024

(in Australian dollars, except number of shares)

	Note	30 June 2024 \$	30 June 2023 \$
Revenue	1A	7,664,784	8,686,118
Finance income	5	119,511	220,161
Other income	2	1,848,731	1,836,822
Changes in inventories		119,425	72,257
Raw materials		(3,879,735)	(4,407,522)
Commissions		(216,414)	(236,019)
Employee benefits expenses	3	(7,586,107)	(6,208,066)
Advertising and promotional expenses		(2,609,314)	(2,712,353)
Professional fees		(1,285,061)	(1,360,640)
Research and development expenses		(752,754)	(1,281,157)
Depreciation and amortization		(534,888)	(676,583)
Impairment expenses		(1,332,000)	(2,125,725)
Other expenses	4	(3,521,774)	(3,687,030)
Finance costs	5	(51,622)	(29,515)
<b>Loss from operations before income tax</b>		<b>(12,017,219)</b>	<b>(11,909,252)</b>
Income tax credit	6	-	158,329
<b>Loss for the year</b>		<b>(12,017,219)</b>	<b>(11,750,923)</b>
<b>Other comprehensive income/(loss)</b>			
Exchange gains/(losses) on translation of controlled foreign operations		(16,266)	100,589
<b>Other comprehensive income/(loss) for the year, net of tax</b>		<b>(16,266)</b>	<b>100,589</b>

Consolidated statement of profit or loss and other comprehensive income  
For the year ended 30 June 2024  
(continued)

<b>Total comprehensive loss attributable to the members of Genetic Technologies Ltd</b>		(12,033,485)	(11,650,334)
---	--	--------------	--------------

<b>Loss per share (cents per share)</b>			
Basic and diluted net loss per ordinary share	7	(0.010)	(0.012)
Weighted-average shares outstanding	7	11,544,779,454	10,138,075,003

The above consolidated statement of profit or loss and comprehensive income should be read in conjunction with the accompanying notes.

Consolidated statement of financial position

As at 30 June 2024

	Note	2024 A\$	2023 A\$
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	8	1,020,608	7,851,197
Trade and other receivables	9	2,126,553	1,921,657
Inventories		206,468	325,893
Other current assets	10	341,746	399,048
<b>Total current assets</b>		<b>3,695,375</b>	<b>10,497,795</b>
<b>Non-current assets</b>			
Right-of-use assets	16	211,796	509,553
Property, plant and equipment	11	52,695	89,623
Goodwill	12	1,784,893	3,116,893
Other intangible assets	13	360,064	520,472
Deferred tax asset		81,698	121,901
<b>Total non-current assets</b>		<b>2,491,146</b>	<b>4,358,442</b>
<b>Total assets</b>		<b>6,186,521</b>	<b>14,856,237</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Trade and other payables	14	2,030,523	1,617,333
Borrowings	17	643,546	-
Contract liabilities	1C	741,647	849,212
Provisions	15	571,028	541,930
Lease liabilities	16	208,719	303,570
<b>Total current liabilities</b>		<b>4,195,463</b>	<b>3,312,045</b>

Consolidated statement of financial position  
As at 30 June 2024  
(continued)

**Non-current liabilities**

Provisions	15	56,021	30,439
Lease liabilities	16	22,924	229,276
Deferred tax liability		81,698	121,901
<b>Total non-current liabilities</b>		<b>160,643</b>	<b>381,616</b>
<b>Total liabilities</b>		<b>4,356,106</b>	<b>3,693,661</b>
<b>Net assets</b>		<b>1,830,415</b>	<b>11,162,576</b>

**EQUITY**

Contributed equity	18	163,817,863	161,342,707
Reserves	19	4,388,628	6,535,556
Accumulated losses	20	(166,376,076)	(156,715,687)
<b>Total equity</b>		<b>1,830,415</b>	<b>11,162,576</b>

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.



Consolidated statement of cash flows  
For the year ended 30 June 2024

	Note	2024 A\$	2023 A\$
<b>Cash flows used in operating activities</b>			
Receipts from customers		7,885,121	8,771,325
Payments to suppliers and employees		(19,312,398)	(20,453,567)
R&D tax incentive and other grants received		1,748,230	1,959,147
<b>Net cash flows used in operating activities</b>		<b>(9,679,048)</b>	<b>(9,723,095)</b>
<b>Cash flows from/(used in) investing activities</b>			
Purchases of plant and equipment		(32,967)	(17,552)
Interest received		147,867	191,803
Payment for purchase of business, net of cash acquired		-	(486,188)
<b>Net cash flows from/(used in) investing activities</b>		<b>114,900</b>	<b>(311,937)</b>
<b>Cash flows from financing activities</b>			
Proceeds from the issue of shares		2,577,147	7,172,399
Proceeds from borrowings		601,000	-
Equity transaction costs		-	(916,060)
Principal elements of lease payments		(348,906)	(336,396)
Interest paid		(6,847)	-
<b>Net cash flows from financing activities</b>		<b>2,822,393</b>	<b>5,919,943</b>
<b>Net decrease in cash and cash equivalents</b>		<b>(6,741,755)</b>	<b>(4,115,089)</b>
Cash and cash equivalents at beginning of year		7,851,197	11,731,325
Net foreign exchange difference		(88,834)	234,961
<b>Cash and cash equivalents at end of year</b>		<b>1,020,608</b>	<b>7,851,197</b>

The above consolidated statements of cash flows should be read in conjunction with the accompanying notes.

Consolidated statement of changes in equity  
For the year ended 30 June 2024

	Contributed equity	Reserves	Accumulated losses	Total equity
	A\$	A\$	A\$	A\$
<b>Balance at June 30, 2022</b>	<b>155,138,636</b>	<b>11,498,651</b>	<b>(150,206,216)</b>	<b>16,431,071</b>
Loss for the year	-	-	(11,750,923)	(11,750,923)
Other comprehensive income	-	100,589	-	100,589
<b>Total comprehensive loss</b>	<b>-</b>	<b>100,589</b>	<b>(11,750,923)</b>	<b>(11,650,334)</b>
<b>Transactions with owners in their capacity as owners</b>				
Contributions of equity, net of transaction costs	6,256,339	-	-	6,256,339
Valuation of warrants	(134,956)	134,956	-	-
Exercise of performance rights	82,688	(82,688)	-	-
Options/warrants expired	-	(5,241,452)	5,241,452	-
Issue of performance rights	-	125,500	-	125,500
	6,204,071	(5,063,684)	5,241,452	6,381,839
<b>Balance at June 30, 2023</b>	<b>161,342,707</b>	<b>6,535,556</b>	<b>(156,715,687)</b>	<b>11,162,576</b>
Loss for the year	-	-	(12,017,219)	(12,017,219)
Other comprehensive income	-	(16,266)	-	(16,266)
<b>Total comprehensive loss</b>	<b>-</b>	<b>(16,266)</b>	<b>(12,017,219)</b>	<b>(12,033,485)</b>
<b>Transactions with owners in their capacity as owners</b>				
Contributions of equity, net of transaction costs	2,577,147	-	-	2,577,147
Valuation of warrants	(101,991)	101,991	-	-
Exercise of performance rights	-	124,177	-	124,177
Options/warrants expired	-	(2,356,830)	2,356,830	-
	2,475,156	(2,130,662)	2,356,830	2,701,324
<b>Balance at June 30, 2024</b>	<b>163,817,863</b>	<b>4,388,628</b>	<b>(166,376,076)</b>	<b>1,830,415</b>

The above consolidated statements of changes in equity should be read in conjunction with the accompanying notes.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended June 30, 2024

1. REVENUE AND DEFERRED INCOME

1A. REVENUE

	2024 A\$	2023 A\$
Sales of EasyDNA branded test - point in time	6,162,865	7,698,605
Sales of AffinityDNA branded test - point in time	1,367,834	944,058
Sales of geneType branded test - point in time	134,085	43,455
<b>Total revenue from contract with customers</b>	<b>7,664,784</b>	<b>8,686,118</b>

1B. DISAGGREGATION OF REVENUE FROM CONTRACTS WITH CUSTOMERS

The Group's revenue disaggregated by primary geographical markets is as follows:

	2024 A\$	2023 A\$
America and Canada	1,666,961	2,242,169
Europe Middle East and Africa	4,069,799	4,494,626
Latin America	190,422	322,033
Asia Pacific	1,737,602	1,627,290
<b>Total revenue</b>	<b>7,664,784</b>	<b>8,686,118</b>

1C. CONTRACT BALANCES

	Note	2024 A\$	2023 A\$
Receivables, which are included in 'net trade receivables'	9	209,254	1,049,393
Contract liabilities		741,647	849,212

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

1C. CONTRACT BALANCES (continued)

Contract liabilities arises from revenue for all business units, which is the consideration received in respect of unsatisfied performance obligation. There are no contract assets as at 30 June 2024 (2023: Nil).

The amount of A\$849,212 included in deferred income (contract liabilities) at 30 June 2023 has been recognized as revenue in 2024.

No revenue was recognized in 2024 from performance obligations satisfied (or partially satisfied) in previous periods (2023: Nil, 2022: Nil).

2. OTHER INCOME

	2024 A\$	2023 A\$
Research and development tax incentive income (1)	1,987,253	1,616,064
Other income	20,763	45,724
Net unrealized foreign exchange gain / (loss)	(139,540)	152,963
Net realized foreign exchange gain / (loss)	(19,745)	22,071
<b>Total other income</b>	<b>1,848,731</b>	<b>1,836,822</b>

(1) R&D tax incentive

The Company's research and development activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognized when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the year ended June 30, 2024, the Company has included an item in other income of A\$1,987,253 (2023: A\$1,616,064) to recognize income over the period necessary to match the grant on a systematic basis with the costs that they are intended to compensate.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

3. EMPLOYEE BENEFITS EXPENSE

	2024 A\$	2023 A\$
Salaries and wages	6,351,193	4,938,516
Director fees	262,725	288,024
Superannuation contribution	417,145	415,128
Share-based payments	124,177	125,500
Other employee costs	430,867	440,898
<b>Total employee benefits expenses</b>	<b>7,586,107</b>	<b>6,208,066</b>

4. OTHER EXPENSES

	2024 A\$	2023 A\$
Buildings and facilities costs	748,864	695,844
Insurance	437,004	403,167
Investor relations and shareholder maintenance	349,441	469,151
Net unrealized foreign exchange loss	-	13,521
Bank and credit card merchant charges	391,627	426,589
IT and communication	627,169	670,008
Travel and entertainment	292,335	366,920
Administrative	281,898	370,571
Other expenses	393,436	271,259
<b>Total other expenses</b>	<b>3,521,774</b>	<b>3,687,030</b>

For personal use only

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. FINANCE INCOME / (FINANCE COSTS)

	2024 A\$	2023 A\$
Interest income	119,511	220,161
<b>Total finance income</b>	<b>119,511</b>	<b>220,161</b>
Lease interest	(17,639)	(29,515)
Interest paid	(33,983)	-
<b>Total finance costs</b>	<b>(51,622)</b>	<b>(29,515)</b>

6. INCOME TAX CREDIT/(EXPENSE)

	2024 A\$	2023 A\$
<b>Reconciliation of income tax expense to prima facie tax payable</b>		
Loss before income tax credit	(12,017,219)	(11,909,252)
Tax at the Australian tax rate of 25% (2023: 25%)	(3,004,305)	(2,977,313)

Tax effect amounts which are not deductible/(taxable)  
in calculating taxable income

	2024 A\$	2023 A\$
Share-based payments expense	31,044	31,375
Research and development tax incentive	1,056,910	919,785
Impairment of goodwill	333,000	461,250
Other assessable items	77,251	-
Income tax expenses before unrecognized tax losses	(1,506,101)	(1,564,903)
Difference in overseas tax rates	(1,873)	53,673

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. INCOME TAX CREDIT/(EXPENSE) (continued)

	2024	2023
	A\$	A\$
Over provision in prior years	(1,224,784)	(454,928)
Temporary differences not recognized	588,722	29,979
Research and development tax credit	(496,813)	(404,016)
Tax losses not recognized	2,660,456	2,543,441
Utilization of tax losses not previously recognized	(19,607)	(361,575)
<b>Income tax credit</b>	<b>-</b>	<b>(158,329)</b>

	2024	2023
	A\$	A\$
<b>Net deferred tax assets</b>		
<b>Deferred tax liabilities recognized</b>		
Brands and trademarks	(81,799)	(121,901)
<b>Total deferred tax liabilities</b>	<b>(81,799)</b>	<b>(121,901)</b>
<b>Deferred tax assets recognized</b>		
Tax losses	81,799	121,901
<b>Total deferred tax assets</b>	<b>81,799</b>	<b>121,901</b>
<b>Deferred tax assets not recognized</b>		
Trade debtor	-	222,144
Capital raising costs	313,518	582,168
Intangible assets	1,058,658	1,407,570

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. INCOME TAX CREDIT/(EXPENSE) (continued)

	2024	2023
	A\$	A\$
Provisions	502,950	342,252
Total deferred tax assets	1,875,127	2,554,134
<b>Deferred tax liabilities not recognized</b>		
Right-of-use assets	(37,102)	(127,388)
Total deferred tax liabilities	(37,102)	(127,388)
Net deferred tax assets on temporary differences not brought to account	(1,838,025)	(2,426,746)

	2024	2023
	A\$	A\$
Tax losses		
Unused tax losses for which no deferred tax asset has been recognized	128,351,776	119,096,654
Potential tax benefit	31,040,867	28,539,512
Potential tax benefit @ 26% (Australia)	24,675,913	21,897,732
Potential tax benefit @ 21% (USA)	6,006,091	6,568,458
Potential tax benefit @ 35% (Malta)	339,290	65,895
Potential tax benefit @ 19% (UK)	19,572	7,427

Subject to the Company continuing to meet the relevant statutory tests, the tax losses are available for offset against future taxable income.

At June 30, 2024, the Company had a potential tax benefit related to tax losses carried forward of A\$31,040,867 (2023: A\$28,539,512). Such amount includes net losses of A\$6,006,091 (2023: A\$6,568,458) related to subsidiaries in the United States (U.S.). The Tax Cuts and Jobs Act (TCJA) enacted by Congress in the U.S. on December 22, 2017 cut the top corporate income tax rate from 35% to 21%. For tax years beginning after December 31, 2017, the graduated corporate tax rate structure is eliminated and corporate taxable income will be taxed at 21% flat rate. Additionally, the previous 20-year limitation on carry forward net operating losses (NOL's) has been removed, allowing the NOL's to be carried forward indefinitely. The remaining tax losses carried forward of A\$24,675,913 (2023: A\$21,897,732) are indefinite and are attributable to the Company's operations in Australia, as well as A\$339,290 (2023: A\$65,895) and A\$19,572 (2023: A\$7,427) tax losses attributable to Company's operations in Malta and UK, respectively. As such the total unused tax losses available to the Company, equal A\$31,040,867 (2023: A\$28,539,511).



## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

### 6. INCOME TAX CREDIT/(EXPENSE) (continued)

As at balance date, there are unrecognized tax losses with a benefit of approximately A\$31,040,867 (2023: A\$28,539,511) that have not been recognized as a deferred tax asset to the Company. These unrecognized deferred tax assets will only be obtained if:

- (a) The Company derives future assessable income of a nature and amount sufficient to enable the benefits to be realized;
- (b) The Company continues to comply with the conditions for deductibility imposed by the law; and
- (c) No changes in tax legislation adversely affect the Company from realizing the benefit.

Management has assessed the tax position of the Company and concluded that any potential uncertainty does not have a material impact on the financial statements.

#### Tax consolidation legislation

Genetic Technologies Limited and its wholly owned Australian subsidiaries implemented the tax consolidation legislation as from July 1, 2003.

The entities in the tax consolidated Company have entered into a Tax Sharing Agreement which, in the opinion of the Directors, limits the joint and several liabilities of the wholly owned entities in the case of a default by the head entity, Genetic Technologies Limited.

The entities have also entered into a Tax Funding Agreement under which the wholly owned entities fully compensate Genetic Technologies Limited for any current tax payable assumed and are compensated by Genetic Technologies Limited for any current tax receivable and deferred tax assets relating to unused tax losses or unused tax credits that are transferred to Genetic Technologies Limited under the tax consolidation legislation. The funding amounts are determined by reference to the amounts recognized in the respective subsidiaries' financial statements.

The amounts receivable or payable under the Tax Funding Agreement are due upon receipt of the funding advice from the head entity, which is issued as soon as practicable after the end of each financial year.

As at June 30, 2024, there are no unrecognized temporary differences associated with the Company's investments in subsidiaries, as the Company has no liability for additional taxation should unremitted earnings be remitted (2023: Nil).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. LOSS PER SHARE

The following reflects the income and share data used in the calculations of basic and diluted loss per share:

	2024 A\$	2023 A\$
Loss for the year	(12,017,219)	(11,750,923)
Weighted average number of Ordinary Shares used in calculating loss per share (number of shares)	11,544,779,454	10,138,075,003

8. CASH AND CASH EQUIVALENTS

	2024 A\$	2023 A\$
Cash at bank and on hand	1,020,608	7,851,197
Total cash and cash equivalents	1,020,608	7,851,197

9. TRADE AND OTHER RECEIVABLES (CURRENT)

	2024 A\$	2023 A\$
Trade receivables	209,254	1,080,479
Less: impairment loss	-	(888,576)
Net trade receivables	209,254	191,903
Other receivables <sup>(1)</sup>	1,917,299	1,729,754
<b>Total net current trade and other receivables</b>	<b>2,126,553</b>	<b>1,921,657</b>

(1) Other receivables includes the R&D tax incentive refund accrued for the 2024 financial year A\$1,839,023 (2023: A\$1,616,064) plus GST receivable A\$78,276 (2023: A\$113,690).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. OTHER CURRENT ASSETS

	2024 A\$	2023 A\$
Prepayments	322,956	381,608
Bonds and deposits	18,790	17,440
<b>Total current prepayments and other assets</b>	<b>341,746</b>	<b>399,048</b>

11. PROPERTY, PLANT AND EQUIPMENT

	2024 A\$	2023 A\$
Laboratory equipment, at cost	973,778	975,619
Less: cost written-off during the year		(8,243)
Add: additions during the year	21,976	6,402
Less: accumulated depreciation	(973,593)	(941,545)
Add: accumulated depreciation written-off during the year		8,243
<b>Net laboratory equipment</b>	<b>22,161</b>	<b>40,476</b>
Computer equipment, at cost	289,265	292,817
Less: cost written-off during the year	(8,490)	(3,099)
Less: cost transferred	-	(11,603)
Add: additions during the year	10,639	11,150
Less: accumulated depreciation	(270,821)	(261,580)
Add: accumulated depreciation transferred	-	11,897
Add: accumulated depreciation written-off during the year	8,490	3,099
<b>Net computer equipment</b>	<b>29,083</b>	<b>42,681</b>
Office equipment, at cost	30,312	18,709
Add: cost transferred	-	11,603
Add: additions during the year	352	-
Less: accumulated depreciation	(29,213)	(11,949)
Less: accumulated depreciation transferred	-	(11,897)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

11. PROPERTY, PLANT AND EQUIPMENT (continued)

	2024	2023
	A\$	A\$
Net office equipment	1,451	6,466
<b>Total net property, plant and equipment</b>	<b>52,695</b>	<b>89,623</b>

Reconciliation of property, plant and equipment		
Opening gross carrying amount	1,290,605	1,284,395
Add: additions purchased during the year	32,967	17,552
Less: cost written-off during the year	(8,490)	(11,342)
<b>Closing gross carrying amount</b>	<b>1,315,082</b>	<b>1,290,605</b>
Opening accumulated depreciation and impairment losses	(1,200,982)	(978,220)
Add: accumulated depreciation written-off during the year	8,490	11,342
Less: cost written-off during the year	(76,699)	(234,697)
Add: foreign currency translation	6,804	593
<b>Closing accumulated depreciation and impairment losses</b>	<b>(1,262,387)</b>	<b>(1,200,982)</b>
<b>Total net property, plant and equipment</b>	<b>52,695</b>	<b>89,623</b>

Reconciliation of movements in property, plant and equipment by asset category for the year ended June 30, 2024

Asset category	Opening net carrying Amount A\$	Additions during year A\$	Transfer during year A\$	Depreciation expense A\$	Foreign currency translation A\$	Closing net carrying amount A\$
Laboratory equipment	40,476	21,976	-	(40,290)	(1)	22,161
Computer equipment	42,681	10,639	-	(30,990)	6,753	29,083
Office equipment	6,466	352	-	(5,419)	52	1,451
<b>Totals</b>	<b>89,623</b>	<b>32,697</b>	<b>-</b>	<b>(76,699)</b>	<b>6,804</b>	<b>52,695</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

11. PROPERTY, PLANT AND EQUIPMENT (continued)

Reconciliation of movements in property, plant and equipment by asset category for the year ended June 30, 2023

Asset category	Opening net carrying Amount A\$	Additions during year A\$	Transfer during year A\$	Depreciation expense A\$	Foreign currency translation A\$	Closing net carrying amount A\$
Laboratory equipment	231,004	6,402	-	(196,928)	(2)	40,476
Computer equipment	62,631	11,150	294	(31,394)	-	42,681
Office equipment	12,540	-	(294)	(6,375)	595	6,466
<b>Totals</b>	<b>306,175</b>	<b>17,552</b>	<b>-</b>	<b>(234,697)</b>	<b>593</b>	<b>89,623</b>

12. GOODWILL

The following table shows the movements in goodwill:

	2024 A\$	2023 A\$
Gross carrying amount:		
Balance at beginning of period	4,961,893	4,506,653
Acquired through business combination	-	455,240
Balance at end of period	4,961,893	4,961,893
Accumulated impairment:		
Balance at beginning of period	(1,845,000)	-
Impairment loss recognized	(1,332,000)	(1,845,000)
Balance at end of period	(3,177,000)	(1,845,000)
Carrying amount at the end of the period	<b>1,784,893</b>	<b>3,116,893</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

12. GOODWILL (continued)

(i) Impairment testing for CGUs containing goodwill

For the purpose of impairment testing, goodwill has been allocated to the Group's CGUs as follows:

	2024	2023
	A\$	A\$
Net carrying amount at the end of the period:		
EasyDNA	1,329,653	2,661,653
AffinityDNA	455,240	455,240
Goodwill allocation at 30 June 2024	<b>1,784,893</b>	<b>3,116,893</b>

(ii) Impairment charge for goodwill

*EasyDNA*

Based upon the impairment testing undertaken by management for the financial year ending June 30, 2024 an impairment loss of A\$1,332,000 (2023: 1,845,000) was recorded for the goodwill asset recorded as part of the EasyDNA business acquisition indicating that the carrying value exceeded the recoverable amount of the CGU as at 30 June 2024. Although significant revenue was recorded in the financial year for EasyDNA, revenue did not meet forecast expectations. Management believes there were a number of contributing factors, including increased competition for the genetic tests offered by EasyDNA, loss of access to pet DNA tests and regulatory changes in France banning sales of paternity tests there.

Following the impairment loss recognized in the Group's EasyDNA CGU, the recoverable amount was equal to the carrying amount. Therefore, any adverse movement in a key assumption would lead to further impairment.

*AffinityDNA*

Management's assessment of impairment for AffinityDNA did not result in an impairment for AffinityDNA as the recoverable amounts exceeds its carrying value by A\$308,000.

Sensitivity analysis undertaken on the key impairment model assumptions indicates that in order for the recoverable amount to be equal to their carrying value for AffinityDNA, the discount rate would need to increase to 20.0% and revenue growth rate would need to decrease by 1.8 percentage points. Management is not aware of any events that are expected to have an adverse effect on revenue growth.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

13. OTHER INTANGIBLE ASSETS

The following table shows the movements in other intangible assets:

	2024	2023
	A\$	A\$
Other intangible assets:		
Gross carrying amount		
Balance at beginning of period	794,682	753,418
Brands, trademark and trade names, acquired through business combination	-	41,264
Balance at end of period	<u>794,682</u>	<u>794,682</u>
Accumulated amortization:		
Balance at beginning of period	(274,210)	(128,498)
Amortization for the period	(160,408)	(145,712)
Balance at end of period	(434,618)	(274,210)
Carrying amount at the end of the period	<u>360,064</u>	<u>520,472</u>

14. TRADE AND OTHER PAYABLES (CURRENT)

	2024	2023
	A\$	A\$
Trade payables	<u>1,458,181</u>	<u>837,952</u>
Accrued expenses	378,905	618,163
Other payables	193,437	161,218
<b>Total current trade and other payables</b>	<b><u>2,030,523</u></b>	<b><u>1,617,333</u></b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

15. PROVISIONS (CURRENT AND NON-CURRENT)

	2024 A\$	2022 A\$
<b>Current provisions</b>		
Annual leave	404,269	328,924
Long service leave	75,169	121,416
Make good <sup>(1)</sup>	91,590	91,590
<b>Total current provisions</b>	<b>571,028</b>	<b>541,930</b>
<b>Non-current provisions</b>		
Long service leave	56,021	30,439
<b>Total non-current provisions</b>	<b>56,021</b>	<b>30,439</b>
<b>Total provisions</b>	<b>627,049</b>	<b>572,369</b>

(1) Make good provision in respect of the lease of the Melbourne office and laboratory

	2024 A\$	2023 A\$
<b>Reconciliation of annual leave provision</b>		
Balance at the beginning of the financial year	328,924	312,665
Add: obligation accrued during the year	532,366	400,780
Less: utilized during the year	(365,705)	(388,457)
Less: paid off during the year	(91,316)	3,936
<b>Balance at the end of the financial year</b>	<b>404,269</b>	<b>328,924</b>
<b>Reconciliation of long service leave provision</b>		
Balance at the beginning of the financial year	151,855	229,304
Add: obligation accrued during the year	35,779	21,723
Less: reversal during the year	(56,444)	(472)
Less: paid off during the year	-	(98,700)
<b>Balance at the end of the financial year</b>	<b>131,190</b>	<b>151,855</b>



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

16. RIGHT-OF-USE ASSET / (LEASE LIABILITIES)

(a) Amounts recognized in the statement of financial position

The statement of financial position shows the following amounts relating to leases:

	2024	2023
	A\$	A\$
<b>Right-of-use assets</b>		
Right-of-use assets	211,796	509,553
<b>Lease Liabilities</b>		
Lease liabilities - Current	(208,719)	(303,570)
Lease liabilities - Non-Current	(22,924)	(229,276)
<b>Total</b>	<b>(231,643)</b>	<b>(532,846)</b>

(b) Amounts recognized in the statement of profit or loss

The statement of profit or loss under general and administrative expenses includes the following amounts relating to leases:

	2024	2023
	A\$	A\$
<b>Depreciation charge of right-of-use assets</b>		
Depreciation Expense (for Leased Assets)	297,780	296,174
Interest expense (included in finance costs)	17,639	29,515
Low value leases	32,094	32,094

During the financial year ended June 30, 2024, the total cash outflow was A\$348,906 (2023: A\$336,396).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

17. BORROWINGS

	2024 A\$	2023 A\$
R&D loan	601,000	0
Insurance premium funding	42,546	0
<b>Total current borrowings</b>	<b>643,546</b>	<b>0</b>

On 25 March 2024 the Group received a secured loan of \$601,000 from Radium Capital. The loan is secured against the anticipated R&D tax incentive refund for the year ended 30 June 2024 and attracts interest at 1.33% per month. The amount of the loan represents 80% of the estimated R&D tax refund based on qualifying expenditure for the six months to 31 December 2023. The loan plus any interest are payable upon receipt of the Group's R&D refund.

In November 2023 the Group entered into a funding agreement with First Insurance to finance part of the Group's annual insurance program of approximately A\$271,000 over a 9-month period. At balance date the amount remaining outstanding is \$42,546.

18. CONTRIBUTED EQUITY

	2024 A\$	2023 A\$
<b>Issued and paid-up capital</b>		
Fully paid Ordinary Shares	163,817,863	161,342,707
<b>Total contributed equity</b>	<b>163,817,863</b>	<b>161,342,707</b>

Movements in shares on issue

Year ended June 30, 2024	Number of Shares	A\$
Balance at the beginning of the financial year	11,541,658,143	161,342,707
Share consolidation	(11,426,240,897)	-
Shares issued during the year	16,800,000	3,111,758
Less: transaction costs arising on share issue	-	(534,611)
Less: valuation of warrants to be issued	-	(101,991)
<b>Balance at the end of the financial year</b>	<b>132,217,246</b>	<b>163,817,863</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

18. CONTRIBUTED EQUITY (continued)

Year ended June 30, 2023	Number of Shares	A\$
Balance at the beginning of the financial year	9,233,965,143	155,138,636
Shares issued during the year	2,307,693,000	7,172,399
Add: Exercise of performance rights	-	82,688
Less: transaction costs arising on share issue <sup>(i)</sup>	-	(916,060)
Less: valuation of warrants to be issued	-	(134,956)
<b>Balance at the end of the financial year</b>	<b>11,541,658,143</b>	<b>161,342,707</b>

Terms and conditions of contributed equity

Ordinary shares have the right to receive dividends as declared and, in the event of winding up the Company, to participate in the proceeds from the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares, which have no par value, entitle their holder to one vote, either in person or by proxy, at a meeting of the Company.

19. RESERVES

	2024 A\$	2023 A\$
Foreign currency translation	831,142	847,408
Share-based payments	3,557,486	5,688,148
<b>Total reserves</b>	<b>4,388,628</b>	<b>6,535,556</b>

	2024 A\$	2023 A\$
<b>Reconciliation of foreign currency translation reserve</b>		
Balance at the beginning of the financial year	847,408	746,819
Add: net currency translation gain / (loss)	(16,266)	100,589
<b>Balance at the end of the financial year</b>	<b>831,142</b>	<b>847,408</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

19. RESERVES (continued)

<b>Reconciliation of share-based payments reserve</b>		
Balance at the beginning of the financial year	5,688,148	10,751,832
Add: share-based payments expense	124,177	-
Add: Issue of performance rights	-	125,500
Add: Valuation of warrants	101,991	134,956
Less: Options/warrants expired	(2,356,830)	(5,241,452)
Less: Exercise of performance rights	-	(82,688)
<b>Balance at the end of the financial year</b>	<b>3,557,486</b>	<b>5,688,148</b>

20. ACCUMULATED LOSSES

	2024 A\$	2023 A\$
Balance at the beginning of the financial year	(156,715,687)	(150,206,216)
Add: net loss attributable to owners of Genetic Technologies Ltd	(12,017,219)	(11,750,923)
Less: Options/warrants expired	2,356,830	5,241,452
<b>Balance at the end of the financial year</b>	<b>(166,376,076)</b>	<b>(156,715,687)</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

21. SUBSIDIARIES

The following diagram is a depiction of the Company structure as at June 30, 2024.

Name of Company	Incorporation details	Company interest (%)		Net carrying value (A\$)	
		2024	2023	2024	2023
<i>Entities held directly by parent</i>					
GeneType Pty. Ltd. (Dormant)	September 5, 1990 Victoria, Australia	100%	100%	-	-
Genetic Technologies Corporation Pty. Ltd. (Genetic testing)	October 11, 1996 NSW, Australia	100%	100%	2	2
Gene Ventures Pty. Ltd. <sup>(1)</sup> (Dormant)	March 7, 2001 NSW, Australia	100%	100%	10	10
GeneType Corporation (Dormant)	December 18, 1989 California, U.S.A.	100%	100%	-	-
geneType Inc. <sup>(2)</sup> (formerly Pheno- gen Sciences Inc.)	June 28, 2010 Delaware, U.S.A.	100%	100%	11,006	11,006
Hainan Aocheng Genetic Technolo- gies Co Ltd	March 18, 2019 Hong Kong, China	100%	100%	-	-
Genetic Technologies HK Ltd	March 18, 2019 Hong Kong, China	100%	100%	-	-
Helix Genetics Limited	July 7, 2021 Malta	100%	100%	1,910	-
Genetype UK Limited	April 26, 2022 United Kingdom	100%	100%	176	-
<b>Total carrying value</b>				<b>13,104</b>	<b>11,018</b>

<sup>(1)</sup> On 26 April 2018, the name of RareCollect Pty Ltd (ACN 096 135 9847) was changed to Gene Ventures Pty Ltd (ACN 096 135 947)

<sup>(2)</sup> On 3 April 2023, the name of Phenogen Sciences Inc. was changed to geneType Inc.